RC48 in Combination With AK104 and Bevacizumab in OCCC

Trial Details

NCT ID

NCT06540729

Phase

PHASE2

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Status

RECRUITING

Cancer Type

Ovarian Cancer

Interventions

• Disitamab vedotin in combination with AK104 and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer

Locations (sample)

• Guanzhou, Guangdong, China|23.06828,113.37117

Key Eligibility Criteria

• The pathological diagnosis confirms ovarian clear cell carcinoma. In cases of mixed carcinoma, a prerequisite is that clear cell carcinoma constitu…
• HER2 IHC ≥1+.
• Treatment-naïve individuals encompass those experiencing tumor progression during postoperative chemotherapy and those who, following platinum-cont…
• Recurrent patients, whether platinum-sensitive or platinum-resistant, include those lacking a platinum-free interval of ≥6 months and who, post-rec…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.